Press Releases
Keyword Search
05.15.23
OpGen Reports First Quarter 2023 Financial Results and Provides Business Update
05.08.23
OpGen to Provide Business Update and Financial Results for the First Quarter 2023 on May 15th at 4:30 p.m. Eastern Time
05.04.23
OpGen Announces Closing of $3.5 Million Public Offering
05.01.23
OpGen Announces Pricing of $3.5 Million Public Offering
04.26.23
OpGen’s Subsidiary Curetis Meets All Remaining Key Milestones in R&D Collaboration with FIND
04.18.23
OpGen Enters Into Distribution Agreement for Unyvero in the U.S. with Fisher Healthcare
04.18.23
OpGen Submits De Novo request to the U.S. FDA for Unyvero Urinary Tract Infection Panel
04.05.23
OpGen’s Subsidiary Curetis Signs Expansion of R&D Collaboration with FIND
04.03.23
OpGen’s Subsidiary Curetis Meets Milestones in Collaborative Research Project with InfectoGnostics
03.30.23
CORRECTION – OpGen Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update